Literature DB >> 30873708

Innate immunity, inflammation and tumour progression: double-edged swords.

A Mantovani1,2,3, A Ponzetta1, A Inforzato1,2, S Jaillon1,2.   

Abstract

Components of the cellular and the humoral arm of the immune system are essential elements of the tumour microenvironment (TME). The TME includes tumour-associated macrophages which have served as a paradigm for the cancer-promoting inflammation. Cytokines, IL-1 in particular, and complement have emerged as important players in tumour promotion. On the other hand, myeloid cells, innate lymphoid cells and complement have the potential, if unleashed, to mediate anticancer resistance. Targeting checkpoints restraining innate immunity, macrophages and natural killer (NK) cells in particular holds promise as a therapeutic strategy.
© 2019 The Association for the Publication of the Journal of Internal Medicine.

Entities:  

Keywords:  inflammation; innate immunity; interleukin-1; macrophages; tumour microenvironment

Mesh:

Substances:

Year:  2019        PMID: 30873708      PMCID: PMC7174018          DOI: 10.1111/joim.12886

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  87 in total

Review 1.  The yin-yang of the interaction between myelomonocytic cells and NK cells.

Authors:  Martina Molgora; Domenico Supino; Domenico Mavilio; Angela Santoni; Lorenzo Moretta; Alberto Mantovani; Cecilia Garlanda
Journal:  Scand J Immunol       Date:  2018-08-19       Impact factor: 3.487

2.  Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer.

Authors:  David S Hong; Filip Janku; Aung Naing; Gerald S Falchook; Sarina Piha-Paul; Jennifer J Wheler; Siqing Fu; Apostolia M Tsimberidou; Michael Stecher; Prasant Mohanty; John Simard; Razelle Kurzrock
Journal:  Invest New Drugs       Date:  2015-03-31       Impact factor: 3.850

3.  Interleukin-1 polymorphisms associated with increased risk of gastric cancer.

Authors:  E M El-Omar; M Carrington; W H Chow; K E McColl; J H Bream; H A Young; J Herrera; J Lissowska; C C Yuan; N Rothman; G Lanyon; M Martin; J F Fraumeni; C S Rabkin
Journal:  Nature       Date:  2000-03-23       Impact factor: 49.962

4.  MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study.

Authors:  Tamas Hickish; Thierry Andre; Lucjan Wyrwicz; Mark Saunders; Tomasz Sarosiek; Judit Kocsis; Radim Nemecek; Wojciech Rogowski; Krzysztof Lesniewski-Kmak; Lubos Petruzelka; Ron N Apte; Prasant Mohanty; Michael Stecher; John Simard; Aimery de Gramont
Journal:  Lancet Oncol       Date:  2017-01-14       Impact factor: 41.316

5.  TNFalpha-induced long pentraxin PTX3 expression in human lung epithelial cells via JNK.

Authors:  Bing Han; Marco Mura; Cristiano F Andrade; Daisuke Okutani; Monika Lodyga; Claudia C dos Santos; Shaf Keshavjee; Michael Matthay; Mingyao Liu
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

Review 6.  The immune contexture in cancer prognosis and treatment.

Authors:  Wolf H Fridman; Laurence Zitvogel; Catherine Sautès-Fridman; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2017-07-25       Impact factor: 66.675

7.  PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer.

Authors:  Eduardo Bonavita; Stefania Gentile; Marcello Rubino; Virginia Maina; Roberto Papait; Paolo Kunderfranco; Carolina Greco; Francesca Feruglio; Martina Molgora; Ilaria Laface; Silvia Tartari; Andrea Doni; Fabio Pasqualini; Elisa Barbati; Gianluca Basso; Maria Rosaria Galdiero; Manuela Nebuloni; Massimo Roncalli; Piergiuseppe Colombo; Luigi Laghi; John D Lambris; Sébastien Jaillon; Cecilia Garlanda; Alberto Mantovani
Journal:  Cell       Date:  2015-02-12       Impact factor: 41.582

8.  M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.

Authors:  Marzia Leidi; Elisa Gotti; Luca Bologna; Elena Miranda; Monica Rimoldi; Antonio Sica; Massimo Roncalli; Giuseppe A Palumbo; Martino Introna; Josée Golay
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

9.  MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study.

Authors:  David S Hong; David Hui; Eduardo Bruera; Filip Janku; Aung Naing; Gerald S Falchook; Sarina Piha-Paul; Jennifer J Wheler; Siqing Fu; Apostolia M Tsimberidou; Michael Stecher; Prasant Mohanty; John Simard; Razelle Kurzrock
Journal:  Lancet Oncol       Date:  2014-04-17       Impact factor: 41.316

10.  IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation.

Authors:  Zhuonan Zhuang; Huai-Qiang Ju; Mitzi Aguilar; Takashi Gocho; Hao Li; Tomonori Iida; Harold Lee; Xiaoqiang Fan; Haijun Zhou; Jianhua Ling; Zhongkui Li; Jie Fu; Min Wu; Min Li; Davide Melisi; Yoichiro Iwakura; Kesen Xu; Jason B Fleming; Paul J Chiao
Journal:  Clin Cancer Res       Date:  2015-10-23       Impact factor: 12.531

View more
  19 in total

Review 1.  Inflammation and Cancer: Triggers, Mechanisms, and Consequences.

Authors:  Florian R Greten; Sergei I Grivennikov
Journal:  Immunity       Date:  2019-07-16       Impact factor: 31.745

2.  Do pentraxin 3 and neural pentraxin 2 have different facet function in hepatocellular carcinoma?

Authors:  Manuela Cabiati; Melania Gaggini; Paolo De Simone; Silvia Del Ry
Journal:  Clin Exp Med       Date:  2021-04-27       Impact factor: 3.984

Review 3.  The Bone Marrow Niche in B-Cell Acute Lymphoblastic Leukemia: The Role of Microenvironment from Pre-Leukemia to Overt Leukemia.

Authors:  Erica Dander; Chiara Palmi; Giovanna D'Amico; Giovanni Cazzaniga
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

Review 4.  Advances in Hypofractionated Irradiation-Induced Immunosuppression of Tumor Microenvironment.

Authors:  Yuxia Wang
Journal:  Front Immunol       Date:  2021-01-25       Impact factor: 7.561

5.  Extracellular vesicles shed from gastric cancer mediate protumor macrophage differentiation.

Authors:  Atene Ito; Shunsuke Kagawa; Shuichi Sakamoto; Kazuya Kuwada; Hiroki Kajioka; Masashi Yoshimoto; Satoru Kikuchi; Shinji Kuroda; Ryuichi Yoshida; Hiroshi Tazawa; Toshiyoshi Fujiwara
Journal:  BMC Cancer       Date:  2021-01-28       Impact factor: 4.430

Review 6.  The NLRP3 Inflammasome and Its Role in the Pathogenicity of Leukemia.

Authors:  Laura Urwanisch; Michela Luciano; Jutta Horejs-Hoeck
Journal:  Int J Mol Sci       Date:  2021-01-28       Impact factor: 5.923

7.  Tumor microenvironment predicts local tumor extensiveness in PD-L1 positive nasopharyngeal cancer.

Authors:  Soehartati A Gondhowiardjo; Marlinda Adham; Lisnawati Rachmadi; Henry Kodrat; Demak Lumban Tobing; I Made Haryoga; Agustinus Gatot Dwiyono; Yoseph Adi Kristian; Tiara Bunga Mayang Permata
Journal:  PLoS One       Date:  2020-03-19       Impact factor: 3.240

Review 8.  Tackling Resistance to Cancer Immunotherapy: What Do We Know?

Authors:  Soehartati A Gondhowiardjo; Vito Filbert Jayalie; Riyan Apriantoni; Andreas Ronald Barata; Fajar Senoaji; Igaa Jayanthi Wulan Utami; Ferdinand Maubere; Endang Nuryadi; Angela Giselvania
Journal:  Molecules       Date:  2020-09-08       Impact factor: 4.411

9.  Staging the Tumor and Staging the Host: Pretreatment Combined Neutrophil Lymphocyte Ratio and Modified Glasgow Prognostic Score Is Associated with Overall Survival in Patients with Esophagogastric Cancers Undergoing Treatment with Curative Intent.

Authors:  Stephen T McSorley; Hiu Y N Lau; David McIntosh; Matthew J Forshaw; Donald C McMillan; Andrew B Crumley
Journal:  Ann Surg Oncol       Date:  2020-09-05       Impact factor: 5.344

Review 10.  Toll-Like Receptors (TLRs), NOD-Like Receptors (NLRs), and RIG-I-Like Receptors (RLRs) in Innate Immunity. TLRs, NLRs, and RLRs Ligands as Immunotherapeutic Agents for Hematopoietic Diseases.

Authors:  Katarzyna Wicherska-Pawłowska; Tomasz Wróbel; Justyna Rybka
Journal:  Int J Mol Sci       Date:  2021-12-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.